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Chronic lymphocytic leukaemia (CLL) is the most common adult leukaemia observed in Europe. The disease is usually
characterised by a long clinical course, however when progression occurs, therapeutic possibilities are limited. Treatment is
palliative and aimed at stabilisation of the disease rather than at achieving complete remission. In patients resistant to
purine analogues prognosis is poor – approximately 40% of patients survive beyond 12 months, with a mean survival of about
8 months. Thus, there is a need for alternative therapeutic procedures, preferably containing agents with a different mode of
action than previously used chemotherapy. Alemtuzumab is a humanized monoclonal antibody directed against the CD52
antigen. This has proven to be an effective alternative in patients with active disease previously treated with alkylating agents
and purine analogues. In our study alemtuzumab was administered to patients with many years’ history of CLL who had
previously receivedvarious other chemotherapeutic regimens. The patients were younger than the median age observed in this
disease. Partial remission of the disease was achieved in 2 cases. One patient attained stabilization of the disease. Rapid
elimination of CD19/CD5+ leukemic cells from peripheral blood and marrow was observed, however regression of enlarged
lymph nodes followed at a much slower rate. The side effects included fever and chills during drug infusion, pancytopoenia and
infections. Basing on previous reports and own observations, it seems that the introduction of alemtuzumab, a therapeutic agent
with a different mode of action than conventional chemotherapy, offers hopes of improving the outcome of treatment of chronic
lymphocytic leukaemia.
Alemtuzumab w leczeniu nawrotów przewlek∏ej bia∏aczki limfatycznej
– opis trzech przypadków
Przewlek∏a bia∏aczka limfatyczna (PBL) jest w Europie najcz´Êciej spotykanà bia∏aczkà u osób doros∏ych. Schorzenie to ma
zazwyczaj wieloletni przebieg kliniczny, jednak w przypadku wystàpienia progresji mo˝liwoÊci terapeutyczne sà ograniczone.
Leczenie ma charakter paliatywny i jest zazwyczaj ukierunkowane na uzyskanie stabilizacji choroby, a nie uzyskanie ca∏ko-
witej remisji choroby. U chorych na CLL, opornych na leczenie analogami puryn, rokowanie jest z∏e, jedynie 40% prze˝ywa
d∏u˝ej ni˝ 12 miesi´cy, a Êredni czas prze˝ycia wynosi ok. 8 miesi´cy. Istnieje zatem potrzeba zastosowania u tych pacjentów
alternatywnych procedur terapeutycznych, najlepiej z u˝yciem preparatów o innym, ni˝ uprzednio stosowane cytostatyki,
mechanizmie dzia∏ania. Alemtuzumab (MabCampath) jest humanizowanym przeciwcia∏em, skierowanym przeciwko anty-
genowi CD52, obecnym m.in. na limfocytach B i T. W Êwietle dotychczas opublikowanych badaƒ klinicznych lek ten okaza∏
si´ skutecznà alternatywà, u chorych z aktywnà chorobà, leczonych uprzednio lekami alkilujàcymi i analogami puryn.
Przedstawiamy opis trzech pacjentów leczonych alemtuzumabem, z wieloletnim przebiegiem choroby, u których stosowano do-
tychczas liczne kursy cytostatyczne. Chorzy ci byli m∏odsi ni˝ wynosi Êrednia wieku dla PBL. W dwóch przypadkach uzyska-
no cz´Êciowà remisj´ choroby, a w jednym stabilizacj´ choroby. We wszystkich przypadkach obserwowano szybkà eliminacj´
bia∏aczkowych komórek CD19/CD5+ z krwi obwodowej i szpiku. Zmniejszanie si´ powi´kszonych w´z∏ów ch∏onnych nast´-
powa∏o znacznie wolniej. Najcz´Êciej wyst´pujàce dzia∏ania niepo˝àdane to goràczka i dreszcze podczas wlewu alemtuzuma-
bu, pancytopenia oraz zaka˝enia. Na podstawie dotychczasowych publikacji oraz obserwacji w∏asnych wydaje si´, ˝e wprowa-
dzenie alemtuzumabu, preparatu o innym, ni˝ konwencjonalne cytostatyki, mechanizmie dzia∏ania przeciwnowotworoweg-
o, stwarza nadziej´ poprawy wyników leczenia przewlek∏ej bia∏aczki limfatycznej.
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Introduction
Chronic lymphocytic leukaemia (CLL) is a malignant
disease in which morphologically mature lymphocytes
accumulate in the blood, bone marrow and the lymphatic
system. It accounts for 30% of all leukaemia cases. Its
incidence in Europe ranges from 1.5 to 3.36 cases per
100.000. The disease usually affects elderly people, the
mean age of patients being more than 65 years, however
about 12% of patients are below 50 years of age.
Therapeutic management of patients suffering from CLL
depends on the stage of the disease and its activity.
Conventional chemotherapy of CLL is based on alkylating
agents, with or without steroids, as well as purine
analogues (fludarabine, 2chlorodeoxyadenosine – 2CdA).
The treatment has a palliative character and is aimed at
stabilisation of the disease rather than at achieving
complete remission [1].
Monoclonal antibodies form a new, promising group
of therapeutic agents, and their use in the treatment of
haematological malignancies is increasing. Alemtuzumab
is a humanized monoclonal antibody directed against
CD52 which is expressed, among others, on B and
T lymphocytes. The alemtuzumab molecule triggers the
mechanisms of cellular lysis by means of antibody-de-
pendent and complement-dependent cell cytotoxicity. It
also has a direct anti-proliferative effect on the malignant
cells. In view of recently published clinical trials, the drug
has proven to be an effective alternative in patients with
active disease who had been previously treated with
alkylating agents and purine analogues [2, 3].
This study presents three CLL patients (2 women
and 1 man, aged 38, 52 and 53 years), in whom alem-
tuzumab was used for the treatment of a consecutive
relapse. All the patients had been previously on cytostatic
protocol, receiving among others, alkylating agents,
anthracyclines and purine analogues. Two patients had
been previously treated with rituximab. The indications
for the use of anti-CD52 antibody included progression of
the disease which had been refractory to the applied
treatment. Alemtuzumab (MabCampath, Schering AG.)
was administered intravenously at standard doses of
30 mg 3 times a week with an escalating dose of 3, 10 and
30 mg during the first week of treatment. Premedication
included clemastin 2 mg i.v. and paracetamol 500 mg
orally. We also instituted infection prophylaxis with
acyclovir and cotrimoxazole.
Case reports
Patient 1 (M.W.) was diagnosed with B-cell chronic
lymphocytic leukaemia in 1992 at the age of 57. She
presented with enlarged lymph nodes and spleen. The
leukocyte count was 29.5 G/l with 80% of mature
lymphocytes in peripheral blood and hemoglobin was
9,89G/l. Rai stage III was established. Prior to alem-
tuzumab treatment, the patient was receiving chemo-
therapy for 8 years, first chlorambucil until 1999, and
then, in view of increasing resistance, CHOP (cyclo-
phosphamide, adriblastin, vincristine, prednisone) for 2
cycles, and next – purine analogues in combination as
FND (fludarabine, mitoxantron, dexamethason) –
altogether 3 cycles. Disease progression was observed
after approx. 6 months and the patient received another,
fourth cycle of FND. The treatment resulted in the
reduction of leukocytosis, and the disease manifested
itself mainly in the form of abdominal lymphadenopathy
(progression of the enlargement of subfascial and
mesenteric lymph nodes which formed clusters in the
hilus of the liver sized 4.5 cm x 2.6 cm and in the caudal
region of the superior mesenteric vein – 8 x 3.3 cm)
(Figure 1). In mid-November 2001 we decided to
introduce alemtuzumab therapy. MabCampath was
administered for 5 weeks at due doses, after which the
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Figure 1. Patient 1. MRI of abdomen. Partial regression of lymph nodes after alemtuzumab therapy
treatment was discontinued due to agranulocytosis (L-0.3
G/l) and pneumonia. The patient was treated with
antibiotics and granulocyte-colony stimulating factor
(G-CSF) and when the symptoms of pneumonia subsided,
she also received immunoglobulins. This resulted in the
increase of leukocyte count, regression of pulmonary
lesions; granulocytosis predominated in the bone marrow
and peripheral blood and bone marrow did not reveal
the presence of CD5/CD19+ cell populations. The
patient remains untreated. A year and a half after the
termination of alemtuzumab therapy, the leukocyte count
remains below 5.0 G/l and the presence of CD5/CD19
cells in peripheral blood and bone marrow appears to be
below 1%. Control abdominal MRI revealed the presence
of a solitary cluster of lymph nodes (Figure 1).
Patient 2. E.M. aged 38. Stage II of CLL according to
Rai, was diagnosed in 1997. The patient presented with
increased peripheral lymphadenopathy of all groups and
splenomegaly; bone marrow contained 80% lymphocytes.
The leukocyte count in peripheral blood was 26 G/l with
70% of CD19/CD5+ lymphocytes. The patient received
CVP (cyclophosphamide, vinblastine, prednisone), CHOP
and next, in view of poor response, she received 6 cycles
of FND, which provided stabilisation for 18 months.
B symptoms (fever, sweating) and enlarged peripheral
lymph nodes were the reasons for instituting methyl-
prednisolone and, next, rituximab treatment, after which
the disease stabilized for the next 4 months. The indica-
tions for alemtuzumab therapy included progression of
the disease manifested by persistent lympadenopathy,
especially on the neck and in the inguinal region, as well
as in the abdominal cavity. Bone marrow contained 85%
of CD19/CD5+ and CD23+ lymphocytes. Alemtuzumab
treatment lasted from March to May 2002. In the third
week of treatment a 50% regression of cervical and
inguinal lymph nodes was noted. In the fourth week the
patient developed neutropenia of 0.5 G/l and anaemia
requiring substitution. During the first two weeks of
therapy fever was observed on the day of infusion. Six
weeks after termination of therapy the patient developed
progressive disease with recurrent peripheral and
abdominal lymphadenopathy which led to her death.
Patient 3. Z.N. aged 53. The diagnosis of CLL was
established in 1998 on the basis of the findings of
leukocytosis 118.6 G/l with 94% of CD19/5+, CD 20+
and CD 23+ lymphocytes. No anaemia or thrombo-
cytopenia was found. The bone marrow contained 83.2%
of lymphocytes. Physical examination revealed peripheral
generalized lymphadenopathy, splenomegaly and enlar-
ged retroperitoneal lymph nodes on ultrasound imaging.
Rai II stage was diagnosed. The patient was treated with
chlorambucil, which led to a decrease in leukocyte count
to 50 G/l. In June 1999 leukocytosis increased to
80.0 G/l with 96% lymphocytosis and nodular progression
– the patient received three 5-day 2CdA cycles, after
which the leukocyte count fell to 26.0 G/l. In November
1999 the leukocyte count increased to 59.4 G/l, nodular
progression set in and the patient was administered 2
CMC (cyclophosphamide, mitoxantron, 2CdA) cycles.
The treatment was complicated with transient thrombo-
cytopenia. Stabilization of the disease was achieved for
the next 8 months and the leukocyte count remained at
a level of 14 G/l. However, in October 2000, the disease
progressed again with increased leukocytosis (53.2 G/l)
and enlargement of peripheral lymph nodes. The patient
was administered 3 cycles of FC (fludarabine, cyclophos-
phamide). The leukocyte count fell to 6 G/l, however
severe thrombocytopenia complicated the course of
treatment. The disease remained stabilized for 7 months
after treatment after which it relapsed in August 2001,
however purine analogues were not administered due to
accompanying thrombocytopenia. The patient received
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Figure 2. Flow cytometry of peripheral blood. Elimination of the CD19/CD5 (+) population after alemtuzumab therapy in patient 2
3 courses of COP (cyclophosphamid, vincristin, predni-
sone) + rituximab, followed by 4 courses of CHOP.
Alemtuzumab treatment was instituted in April 2002.
During the first infusion the patient developed chills and
pyrexia of 40° C, as well as symptoms of bronchospasm. In
the first three weeks of therapy the leukocyte count fell
from 67.3 G/l to 1.6 G/l. The treatment was discontinued
for about 4 weeks, after which the leukocyte count
increased again to 20 G/l. In May 2002 the patient was
administered alemtuzumab for 3 weeks resulting in the
reduction of leukocytosis which lasted until September
2002, when it increased again to 31.5 G/l. He then
received antiCD52 antibodies. After 3 months’ stabiliza-
tion the disease progressed rapidly with increasing
leukocytosis, in consequence leading to the death of the
patient.
Discussion
Chronic lymphocytic leukaemia is the most common adult
leukaemia occurring in Europe. The disease is usually
characterised by a long clinical course, however when
progression occurs, the therapeutic possibilities are
limited. In patients with CLL who are resistant to purine
analogues the prognosis is poor – approximately 40% of
patients survive beyond 12 months, with a mean survival
of about 8 months [4]. Thus, there is need for alternative
therapeutic procedures, preferably containing agents with
a different mode of action than previously used chemo-
therapy. One of the options includes the use of mono-
clonal antibodies. Alemtuzumab is a humanized
monoclonal antibody directed against the CD52 antigen.
High expression of the antigen (500 000 receptors on one
cell) was found in 95% of normal and malignant B and
T lymphocytes and – to a lesser degree – on monocytes,
macrophages and eosinophilic granulocytes. The CD52
antigen is not present on the CD34 positive stem cells of
the hematopoietic system [5]. The beneficial effect of
almetuzumab therapy in patients with CLL resistant to
previous chemotherapy was confirmed in multicentre
studies. The response (CR + PR) accounts for 30%
[2, 3, 6].
In our study alemtuzumab was administered to
patients with many years’ history of CLL who had
previously received numerous chemotherapeutic
regimens, including alkylating agents and purine
analogues. The patients were younger than the median
age observed in this disease. Partial remission of the
disease was achieved in 2 cases despite the fact that the
patients were in a consecutive relapse, however one
patient developed progression of the disease after sic
weeks and died. One patient attained stabilization of the
disease. Consistently to data in literature, we observed
rapid elimination of CD19/CD5 leukemic cells from
peripheral blood and marrow, however regression of
enlarged lymph nodes followed at a much slower rate
[7-9]. Side effects included fever and chills during the
alemtuzumab infusions, pancytopenia and infections. The
infections were caused by profound immunosuppression
associated with the primary disease (deficiency of
antibodies) as well as with lymphopenia resulting from
the elimination of CD 52+ cells from the peripheral
blood. There were no cytomegalovirus reactivations. In
the case of one patient (M.W.) pneumonia appearing in
the course of leukopenia resulted in discontinuation of
therapy. Despite this complication, the patient remains in
partial remission lasting 18 months. It is worth noting
that in this case the administration of alemtuzumab
followed immediately after fludarabine treatment in the
form of FND. According to Kennedy et al. the com-
bination of anti-CD52 antibody with fludarabine is
effective in refractory CLL, also in patients in whom the
above mentioned agents were used as monotherapy [10].
Severe pancytopenia and infectious complications in the
first two cases were the reason to modify alemtuzumab
doses in the third patient. In this patient the treatment
was aimed leukocyte count stabilisation and thus, when it
was achieved, the treatment was discontinued until the
increase of the white blood count reappeared. Despite
the fact that the CD52 antigen does not occur on
hematopoiesis stem cells, erythrocyte and platelet
substitution was mandatory in all the cases. In two cases
alemtuzumab treatment was administered to patients who
previously received anti-CD20 monoclonal antibody
(rituximab). According to Keating et al., alemtuzumab
may also be effective in CLL patients who were resistant
to rituximab [2]. On the basis of previous reports and
own observations it seems that the introduction of
alemtuzumab, a therapeutic agent with a different mode
of action than conventional chemotherapy, offers hopes of
improving the outcome of treatment of chromic lympho-
cytic leukaemia. At present, clinical studies are led on
the use of alemtuzumab as first-line treatment of CLL
[8]. However, the placement of alemtuzumab in CLL
therapeutic protocols (first line treatment or salvage
treatment, monotherapy or combined therapy?), as well
as the determination of optimum dosage require further
investigations.
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